

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

**SCHEDULE 14A
(Rule 14A-101)**

**INFORMATION REQUIRED IN
PROXY STATEMENT**

SCHEDULE 14A INFORMATION

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

InVivo Therapeutics Holdings Corp.
(Name of Registrant as Specified in its Charter)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1) Title of each class of securities to which transaction applies:

2)

Aggregate number of securities to which transaction applies:

3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

4)

Proposed maximum aggregate value of transaction:

5)

Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

1) Amount Previously Paid:

2)

Form, Schedule or Registration Statement No.:

3)

Filing Party:

4)

Date Filed:



One Kendall Square, Suite B14402
Cambridge, MA 02139

YOUR VOTE IS EXTREMELY IMPORTANT!

July 1, 2021

Dear InVivo Stockholder,

According to our latest records, we have not yet received your voting instructions for the Annual Meeting of Stockholders of **InVivo Therapeutics Holdings Corp.** to be held Friday, July 16, 2021. **Your vote is extremely important.**

Please help us avoid the burden and expense of further solicitation by casting your vote today.

Your vote must be cast no later than 11:59 pm Eastern Time on Thursday, July 15, 2021 to be counted if you do not plan to attend the virtual Annual Meeting.

Voting is easy. Regardless of the number of shares you own, it is important that they be represented at the meeting. Your vote matters to us and we need your support for our continued business activities. Please vote your shares now so that your vote can be counted without delay. You may utilize one of the options below to ensure that your vote is promptly recorded in time for the meeting:


Vote By Internet	Vote During The Meeting	Vote By Mail
<p>http://www.proxyvote.com</p> <p>Use the Internet to transmit your voting instructions until 11:59 p.m. Eastern Time on Thursday, July 15, 2021. Have your proxy card in hand when you access the website. You will be prompted to enter your control number to create and submit an electronic ballot.</p>	<p>In order to attend the Annual Meeting online and vote online during the Annual Meeting, you must register in advance at https://www.cstproxy.com/invivotherapeutics/2021. You may vote your shares online while virtually attending the Annual Meeting by following instructions found on your notice, proxy card and/or voting instruction form.</p>	<p>Mark, sign and date your proxy card and return it in the enclosed postage-paid envelope.</p>

YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!

If you have any questions relating to this Shareholder Meeting or voting your shares, you may call our proxy specialists toll-free at **1-877-787-9239** between the hours of 10:00 a.m. and 6:00 p.m. Monday through Friday Eastern time. You may also contact this number to request additional proxy materials.

Your vote is important, and we urge you to vote. Thank you.

Sincerely,

A handwritten signature in black ink that reads "Richard M. Toselli". The signature is written in a cursive style with a large initial 'R' and a long, sweeping tail.

Richard Toselli, M.D.
President, Chief Executive Officer and Director
